{
    "clinical_study": {
        "@rank": "151296", 
        "arm_group": {
            "arm_group_label": "Treatmen", 
            "arm_group_type": "Experimental", 
            "description": "PM01183 + paclitaxel +/- bevacizumab"
        }, 
        "brief_summary": {
            "textblock": "Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in\n      patients with solid tumors"
        }, 
        "brief_title": "Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Ovarian Cancer", 
            "Gynecological Cancer", 
            "Head and Neck Carcinoma", 
            "Non-small Cell Lung Cancer", 
            "Small Cell Lung Cancer", 
            "Non-squamous Cell Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Ovarian Neoplasms", 
                "Small Cell Lung Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Clinical trial to determine the maximum tolerated dose (MTD) and the recommended dose (RD)\n      of PM01183 in combination with weekly paclitaxel, with or without bevacizumab. Once a\n      recommended dose is defined for the PM01183 and weekly paclitaxel combination, the\n      feasibility of adding bevacizumab to this combination will be explored in a selected cohort\n      of patients to characterize the safety profile and feasibility of this combination, to\n      obtain preliminary information on antitumor activity, to obtain preliminary information on\n      quality of life (QoL), to characterize the pharmacokinetics (PK) of this combination and to\n      detect major drug-drug PK interactions and PK/PD (pharmacokinetic/pharmacodynamic)\n      correlation and to conduct an exploratory pharmacogenomic(PGx) analysis in patients with\n      selected advanced solid tumors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntarily signed and dated written informed consent\n\n          -  Age between 18 and 75 years old (both inclusive)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of \u2264 1\n\n          -  Life expectancy \u2265 3 months.\n\n          -  Patients with a histologically/cytologically confirmed diagnosis of advanced and/or\n             unresectable disease of any of the following tumors:\n\n               1. Breast cancer\n\n               2. Epithelial ovarian cancer or gynecological cancer\n\n               3. Head and neck squamous cell carcinoma\n\n               4. Non-small cell lung cancer\n\n               5. Small cell lung cancer\n\n               6. Platinum-refractory germ-cell tumors.\n\n               7. Adenocarcinoma or carcinoma of unknown primary site\n\n          -  Adequate bone marrow, renal, hepatic, and metabolic function\n\n          -  Recovery to grade \u2264 1 or to baseline from any AE derived from previous treatment\n             (excluding alopecia of any grade).\n\n          -  Pre-menopausal women must have a negative pregnancy test before study entry and agree\n             to use a medically acceptable method of contraception throughout the treatment period\n             and for at least six weeks after treatment discontinuation\n\n        Exclusion Criteria:\n\n          -  Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel\n\n          -  Patients who have previously discontinued paclitaxel-based regimes due to drug\n             related toxicity.\n\n          -  Known hypersensitivity to bevacizumab or any component of its formulation\n\n          -  Patients who have previously discontinued bevacizumab-containing regimes due to\n             drug-related toxicity.\n\n          -  More than three prior lines of chemotherapy\n\n          -  Less than three months since last taxane-containing therapy.\n\n          -  Wash-out period:\n\n               1. Less than three weeks since the last chemotherapy-containing regimen\n\n               2. Less than three weeks since the last radiotherapy dose\n\n               3. Less than four weeks since last monoclonal antibody-containing therapy\n\n          -  Concomitant diseases/conditions:\n\n        Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic\n        attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary\n        embolism within last year, arrhythmia, hepatopathy, uncontrolled infection,  hemoptysis or\n        oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems,\n        peripheral neuropathy, Symptomatic or progressive brain metastases or leptomeningeal\n        disease.\n\n          -  Men or pre-menopausal women who are not using an effective method of contraception as\n             previously described; actively breast feeding women.\n\n          -  Patients who have pelvic irradiation with doses \u2265 45 Grays (Gy).\n\n          -  History of previous bone marrow and/or stem cell transplantation.\n\n          -  Confirmed bone marrow involvement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831089", 
            "org_study_id": "PM1183-A-007-13"
        }, 
        "intervention": {
            "arm_group_label": "Treatmen", 
            "description": "PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion\npaclitaxel: 6 mg/ml concentrate for solution for infusion\nbevacizumab: 25 mg/ml concentrate for solution for infusion\nOnce a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients", 
            "intervention_name": "PM01183 + paclitaxel +/- bevacizumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors", 
        "overall_contact": {
            "email": "sszyldergemajn@pharmamar.com", 
            "last_name": "Sergio Szyldergemajn, MD", 
            "phone": "+34 91-846-6068"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with weekly paclitaxel, with or without bevacizumab, in patients with selected advanced solid tumors.", 
            "measure": "To determine the maximum tolerated dose (MTD) and the recommended dose (RD)", 
            "safety_issue": "Yes", 
            "time_frame": "Around 24 months from the begining of the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831089"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To characterize the pharmacokinetics (PK) and to detect major drug-drug PK interactions", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Around 24 monts after the begining of the study"
            }, 
            {
                "description": "Antitumor activity will be measured clinically and/or radiologically according to the RECIST (Response Evaluation Criteria in Solid Tumors)", 
                "measure": "Preliminary antitumor activity.", 
                "safety_issue": "No", 
                "time_frame": "Every nine weeks, up to around 24 months from the begining of the study"
            }, 
            {
                "description": "Changes in Quality of Life scores over time will be evaluated according to the European Organization for Research and Treatment of Cancer (EORTC) questionnaire EORTC-QLQ-C15-pal", 
                "measure": "Information on quality of life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 9, 18 and 24 weeks"
            }, 
            {
                "description": "Identification and validation of putative molecular markers associated with the clinical outcome of treated patients", 
                "measure": "Pharmacogenomic (PGx)", 
                "safety_issue": "No", 
                "time_frame": "Around 24 months from the begining of the study"
            }
        ], 
        "source": "PharmaMar", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}